Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Yu‐Hui Chen et al.|New England Journal of Medicine|2015Cited by 2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate CancerMario A. Eisenberger, Bruce A. Lowe|New England Journal of Medicine|1998Cited by 868
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)Niven Mehra, Johann S. de Bono, David Dolling et al.|European Urology|2018Cited by 110
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomyEmmanuel S. Antonarakis, Mario A. Eisenberger|Cancer|2012Cited by 107